Literature DB >> 16394652

Death receptor signaling and its function in the immune system.

Stefanie C Fas1, Benedikt Fritzsching, Elisabeth Suri-Payer, Peter H Krammer.   

Abstract

Death receptors belong to the TNF (tumor necrosis factor)/NGF (nerve growth factor) receptor superfamily. Signaling via death receptors plays a distinct role, e.g. in the immune system, where it contributes to regulation of the adaptive immune response in various ways, most notably by triggering activation-induced cell death (AICD) of T cells. Thus, dysregulation of death receptor signaling, either allowing too much or too little apoptosis, can lead to autoimmune disorders and also impacts on tumorigenesis or other diseases. In this chapter we address components, molecular mechanisms and regulation of death receptor signaling with particular focus on CD95 (APO-1, Fas). We discuss the role of death receptor-mediated AICD in regulation of the adaptive immune response against foreign and self antigens in comparison to cytokine deprivation-mediated death by neglect. Finally, the contribution of dysregulated death receptor/ligand systems to autoimmune diseases such as diabetes, multiple sclerosis and Hashimoto's thyroiditis is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394652     DOI: 10.1159/000090767

Source DB:  PubMed          Journal:  Curr Dir Autoimmun        ISSN: 1422-2132


  24 in total

1.  Autoimmune lymphoproliferative syndrome: a multifactorial disorder.

Authors:  Frédéric Rieux-Laucat; Aude Magerus-Chatinet
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

Review 2.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

3.  Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.

Authors:  Christian Schütz; Sabine Hoves; Dagmar Halbritter; Huang-Ge Zhang; John D Mountz; Martin Fleck
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

Review 4.  Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms.

Authors:  Mohammad Athar; Jung Ho Back; Levy Kopelovich; David R Bickers; Arianna L Kim
Journal:  Arch Biochem Biophys       Date:  2009-06-15       Impact factor: 4.013

5.  Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.

Authors:  J Sellner; I Greeve; O Findling; D Grandgirard; S L Leib; H P Mattle
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

6.  Identification and analysis of immune-related transcriptome in Asian seabass Lates calcarifer.

Authors:  Jun Hong Xia; Gen Hua Yue
Journal:  BMC Genomics       Date:  2010-06-04       Impact factor: 3.969

7.  The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo.

Authors:  Lauren A Courter; Andreas Luch; Tamara Musafia-Jeknic; Volker M Arlt; Kay Fischer; Robert Bildfell; Cliff Pereira; David H Phillips; Miriam C Poirier; William M Baird
Journal:  Cancer Lett       Date:  2008-03-18       Impact factor: 8.679

8.  Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death.

Authors:  Charles Sia; Arno Hänninen
Journal:  Rev Diabet Stud       Date:  2006-05-10

9.  Prevention of TNF-induced necrotic cell death by rottlerin through a Nox1 NADPH oxidase.

Authors:  Hee Sun Byun; Minho Won; Kyeong Ah Park; Young-Rae Kim; Byung Lyul Choi; Hyunji Lee; Jang Hee Hong; Longzhen Piao; Jongsun Park; Jin Man Kim; Gi Ryang Kweon; Sung Hyun Kang; Jin Han; Gang Min Hur
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

10.  Frequency of atopy and allergic disorders among adults with Type 1 diabetes mellitus in the southern Marmara region of Turkey.

Authors:  C Duran; D Ediger; C Ersoy; N F Coskun; H Selimoglu; I Ercan; S Kiyici; M Guclu; D A Saglam; E Erturk; E Tuncel; S Imamoglu
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.